REPORT ID 3269

Global Overactive Bladder Drug Market Size, Status and Forecast 2022

Publish Date
13-Dec-17
Pages
101
Format
Electronic (PDF)

This report studies the global Overactive Bladder Drug market, analyzes and researches the Overactive Bladder Drug development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Astellas Pharma, Inc. (Japan)
    Pfizer, Inc. (U.S.)
    Teva Pharmaceutical Industries Limited (Israel)
    Allergan, Plc (Ireland)
    Medtronic plc (Ireland)
    Mylan N.V. (U.S.)
    Endo International plc (Ireland)
    Hisamitsu Pharmaceutical Co., Inc. (Japan)
    Sanofi (France)
    Apotex, Inc. (Canada)
    Cogentix Medical, Inc. (U.S.)
    Aurobindo Pharma Limited (India)

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, the product can be split into
    Anticholinergics
    Solifenacin
    Oxybutynin
    Darifenacin
    Fesoterodine
    Tolterodine
    Trospium
    Others

Market segment by Application, Overactive Bladder Drug can be split into
    Idiopathic Bladder Overactivity
    Neurogenic Bladder Overactivity

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global Overactive Bladder Drug Market Size, Status and Forecast 2022
1 Industry Overview of Overactive Bladder Drug
    1.1  Overactive Bladder Drug Market Overview
        1.1.1 Overactive Bladder Drug Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Overactive Bladder Drug Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Overactive Bladder Drug Market by Type
        1.3.1 Anticholinergics
        1.3.2 Solifenacin
        1.3.3 Oxybutynin
        1.3.4 Darifenacin
        1.3.5 Fesoterodine
        1.3.6 Tolterodine
        1.3.7 Trospium
        1.3.8 Others
    1.4 Overactive Bladder Drug Market by End Users/Application
        1.4.1 Idiopathic Bladder Overactivity
        1.4.2 Neurogenic Bladder Overactivity

2 Global Overactive Bladder Drug Competition Analysis by Players
    2.1 Overactive Bladder Drug Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Astellas Pharma, Inc. (Japan)
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Pfizer, Inc. (U.S.)
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 Teva Pharmaceutical Industries Limited (Israel)
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Allergan, Plc (Ireland)
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Medtronic plc (Ireland)
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 Mylan N.V. (U.S.)
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 Endo International plc (Ireland)
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Sanofi (France)
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Apotex, Inc. (Canada)
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Overactive Bladder Drug Revenue (Value) (2012-2017)
        3.10.5 Recent Developments
    3.11 Cogentix Medical, Inc. (U.S.)
    3.12 Aurobindo Pharma Limited (India)

4 Global Overactive Bladder Drug Market Size by Type and Application (2012-2017)
    4.1 Global Overactive Bladder Drug Market Size by Type (2012-2017)
    4.2 Global Overactive Bladder Drug Market Size by Application (2012-2017)
    4.3 Potential Application of Overactive Bladder Drug in Future
    4.4 Top Consumer/End Users of Overactive Bladder Drug

5 United States Overactive Bladder Drug Development Status and Outlook
    5.1 United States Overactive Bladder Drug Market Size (2012-2017)
    5.2 United States Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

6 EU Overactive Bladder Drug Development Status and Outlook
    6.1 EU Overactive Bladder Drug Market Size (2012-2017)
    6.2 EU Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

7 Japan Overactive Bladder Drug Development Status and Outlook
    7.1 Japan Overactive Bladder Drug Market Size (2012-2017)
    7.2 Japan Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

8 China Overactive Bladder Drug Development Status and Outlook
    8.1 China Overactive Bladder Drug Market Size (2012-2017)
    8.2 China Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

9 India Overactive Bladder Drug Development Status and Outlook
    9.1 India Overactive Bladder Drug Market Size (2012-2017)
    9.2 India Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Overactive Bladder Drug Development Status and Outlook
    10.1 Southeast Asia Overactive Bladder Drug Market Size (2012-2017)
    10.2 Southeast Asia Overactive Bladder Drug Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Overactive Bladder Drug Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
        11.1.2 EU Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
        11.1.4 China Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
        11.1.5 India Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Overactive Bladder Drug Revenue and Growth Rate (2017-2022)
    11.2 Global Overactive Bladder Drug Market Size (Value) by Type (2017-2022)
    11.3 Global Overactive Bladder Drug Market Size by Application (2017-2022)

12 Overactive Bladder Drug Market Dynamics
    12.1 Overactive Bladder Drug Market Opportunities
    12.2 Overactive Bladder Drug Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Overactive Bladder Drug Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Overactive Bladder Drug Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source